研究单位：[1]Beijing Chao Yang Hospital[2]Tongji University[3]The No.180 Hospital of People's Liberation Army[4]Cancer Biology Research Center,Tongji Hospital,Tongji Medical college,Huazhong University of Science and Technology,Wuhan,Hubei 430030,P.R.China
研究目的：
Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC. The advantages of ADV-TK gene therapy highlight its potentiality as adjuvant treatment for HCC patients after LT. We reported here the improved outcome of LT with combined treatment of ADV-TK gene therapy in patients with intermediate or advanced HCC.
